close

India delays big exports of AstraZeneca vaccine as Covid-19 cases surge

India is, however, not officially banning Covid-19 vaccine exports. "This is a temporary move until the supply situation stabilises in the country," said a person close to the development

Sohini DasReuters Mumbai/New Delhi
AstraZeneca, pharma, coronavirus, vaccine
Premium

India has put a temporary hold on all major exports of the AstraZeneca coronavirus vaccine made by Serum Institute of India (SII), the world’s biggest vaccine-maker, to meet domestic demand as infections rise, multiple sources confirmed.
A person close to the development said that in the light of rising demand for Covid-19 vaccines, the health ministry has conveyed to SII that it should prioritise deliveries to the government of India over export commitments. The entire production of 60 million doses in April will be supplied to the government.
India is, however, not officially banning Covid-19 vaccine exports. “This is a temporary move until the supply situation stabilises in the country,” said the person.
Or

Also Read

Coronavirus vaccine update: Mexico gets 1st doses of Chinese vaccine COVAX

Increase vaccine supply

Coronavirus vaccine update: UK, Russia to rollout vaccine from next week

Coronavirus vaccine update: China Covid vaccine gives quick immune response

Covid-19 vaccines not ready for open-market roll-out yet, says govt

88% of Covid-19 deaths in India in age group of 45 years and above: Centre

New 'double mutant' strain of Covid-19 detected in India: Health Ministry

A year since lockdown, Maha, Mumbai set new record highs of Covid-19 cases

Gujarat reports 1,790 new Covid-19 cases, highest one-day rise

India delays big exports of AstraZeneca shot as infections surge: Report

First Published: Mar 25 2021 | 2:10 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers. Already a BS Premium subscriber?LOGIN NOW

Register to read more on Business-Standard.com